On May 30th, Guilong Hui reported that BOC International's research report pointed out that Zhejiang NHU (002001.SZ) had a growth in performance in Q1 24, and improved profitability. On May 24th, the unit price of lysine was 21.82 yuan/kg (+2.15% from the beginning of the year). The rising prices of vitamins and lysine are expected to improve the company's performance in the nutritional sector. In addition, according to the 2023 annual report, the active pharmaceutical ingredient sector has launched Q10 drugs and upgraded product structure according to market demand, and the company has gradually developed into a producer of antipyretic and analgesic drugs, nutritional drugs, and specialty active pharmaceutical intermediates. Considering that the prices of vitamins and lysine are still recovering in 2024, the long-term outlook is for the prosperity of the vitamin and lysine industry to improve with the optimization of the supply and demand pattern. Adjust profit forecasts, and predict that the company's earnings per share will be 1.20 yuan, 1.45 yuan, and 1.71 yuan respectively from 2024 to 2026. Bullish on the performance growth brought about by the rising prices of vitamins and lysine, and the continuous advancement of new projects, maintaining a 'buy' rating.